[全文] 赛诺菲和葛兰素史克宣布推迟他们的COVID-19疫苗计划，以改善老年人的免疫反应:
- 第1/2期中期结果显示，在18至49岁的成年人中，免疫应答与从COVID-19恢复的患者相当
- 老年人的反应不足表明需要改进抗原浓度，以便在所有年龄组中提供高水平的免疫反应
- 公司计划用改进的抗原制剂进行2b期研究
- 在BARDA的支持下，作为Warp-Speed行动的一部分，这项研究将于2021年2月开始，包括一项与授权的COVID-19疫苗的拟议比较
- 在开发计划顺利完成之前，预计2021年第4季度产品可供使用
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
- Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
- Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups
- Companies plan a Phase 2b study with an improved antigen formulation
- With support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccine
- Product availability now expected in Q4 2021 pending successful completion of the development plan  
$赛诺菲-安万特(SNY)$ $葛兰素史克(GSK)$ $辉瑞(PFE)$